A Study of Xiang-Sha-Liu-Jun-Zi-Tang in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome Clinical Trial

Official title:

A Randomized Double Blind Placebo Control Study of Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT)in Patients With Irritable Bowel Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02179580
• Other study ID #: CMUH103-REC2-016
• Status: Recruiting
• Phase: Phase 2/Phase 3
• First received: May 27, 2014
• Last updated: June 30, 2014
• Start date: June 2014
• Est. completion date: December 2015

Study information

• Verified date: June 2014
• Source: China Medical University Hospital
• Contact: Hsueh-Chou Lai
• Phone: +886-4-22052121
• Email: d3145[@]mail.cmuh.org.tw
• Is FDA regulated: No
• Health authority: Taiwan: Department of Health
• Study type: Interventional

Clinical Trial Summary

Ministry of Health and Welfare Department of Chinese Medicine and pharmacy specially subsidizes domestic teaching hospitals to install clinical study centers for Chinese pharmacies, in order to establish the clinical study environment for Chinese pharmacies meeting the international regulations, to assist promoting and performing clinical studies in Chinese pharmacies, and then to improve the nation's health and benefits. This will render Chinese pharmacies competitive in the international market by employing scientific tests and verifications. The new project applications are respectively as follows: A randomized double blind placebo control study of Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT) in patients with irritable bowel syndrome The main clinical manifestations of irritable bowel syndrome (IBS) are chronic, recurrent abdominal pain or abdominal dyscomfortable associated with the changes of defecation habit, such as constipation and/or diarrhea. Clinical treatment of IBS includes behavioral, and drug treatment, such as anti-diarrheal agent, 5-HT3 receptor antagonist and 5-HT4 receptor agonist, but these treatments relieve partial symptoms only. Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT) origins from Yizongjinjion, and that uses XSLJZT to treat the patients who has qi deficiency, phlegm-retained fluid, nausea and vomiting, gastrointestinal dysharmony and producing many symptoms. These symptoms of mentioned-above are similar to IBS. Therefore, the purpose of the present study was to investigate the therapeutic effect of XSLJZT on IBS, the investigators designed a randomized double blind placebo control study to assess the effect of XSLJZT on IBS.

Description:

Ministry of Health and Welfare Department of Chinese Medicine and pharmacy specially subsidizes domestic teaching hospitals to install clinical study centers for Chinese pharmacies, in order to establish the clinical study environment for Chinese pharmacies meeting the international regulations, to assist promoting and performing clinical studies in Chinese pharmacies, and then to improve the nation's health and benefits. This will render Chinese pharmacies competitive in the international market by employing scientific tests and verifications. The new project applications are respectively as follows: A randomized double blind placebo control study of Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT) in patients with irritable bowel syndrome The main clinical manifestations of irritable bowel syndrome (IBS) are chronic, recurrent abdominal pain or abdominal dyscomfortable associated with the changes of defecation habit, such as constipation and/or diarrhea. Clinical treatment of IBS includes behavioral, and drug treatment, such as anti-diarrheal agent, 5-HT3 receptor antagonist and 5-HT4 receptor agonist, but these treatments relieve partial symptoms only. Xiang-Sha-Liu-Jun-Zi-Tang (XSLJZT) origins from Yizongjinjion, and that uses XSLJZT to treat the patients who has qi deficiency, phlegm-retained fluid, nausea and vomiting, gastrointestinal dysharmony and producing many symptoms. These symptoms of mentioned-above are similar to IBS. Therefore, the purpose of the present study was to investigate the therapeutic effect of XSLJZT on IBS, we designed a randomized double blind placebo control study to assess the effect of XSLJZT on IBS.

In addition to the performance of the clinical study projects for Chinese pharmacies, our center will still maintain cooperation with domestic or foreign biotechnology industries, the industries of Chinese herbal medicine and academic research institutes, such as the material research institute in Industrial Technology Research Institute, Feng Chia University, and Yuanpei University, make efforts in expanding the study in the development of novel Chinese medicinal drugs and novel medical techniques, and cooperate with famous international Contract Research Organizations (CRO). We want to build a clinical study service platform, in which the internal part is to integrate various R&D units on campuses and hospitals, such as the teams in the department of medical care, department of medical technology, all laboratories, the incubation center, the biostatistics center, the administrative department and improve the internal procedures for performing clinical studies. The external part is to make efforts to win over domestic and foreign clinical study cases to be performed in our center. The performing methods are illustrated as follows:

1. Setting up the environment and related equipment that enable the performance of clinical studies in Chinese pharmacies and establishing the operation manuals and standard operation procedures for performing the R&D stage for drugs of Chinese pharmacies.

2. Employing professionals required in the clinical study in Chinese pharmacies and encouraging doctors, pharmacists and nurses to attend advanced study and receive training while enhancing the incubation for the required professionals of clinical studies, such that the experience can be passed to others.

3. Practically performing one or more proposals of developing new drugs of Chinese pharmacies or the clinical study proposal of reassessing therapeutic efficacies of drugs in the drug permission certificates issued by the Committee on Chinese Medicine and Pharmacy on record.

4. Promoting and building an intact and strong audit system in accordance with Good Clinical Practice (GCP), elevating the clinical study level in our country, and putting the regulations of GLP into practice.

5. Promoting the cooperation with industries, academics, and governments and international cooperation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 2015
• Est. primary completion date: December 2015
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 20 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Age : from 20 y/o to 65 y/o.

2. Gender : male or female.

Exclusion Criteria:

1. Pregnant or lactating.

2. Elevated serum ALT / AST level (3 x upper limit of normal (ULN)),or greater than normal serum Creatinine.

3. The clients with psychological cannot cooperate with each other. ( ex. depression, schizophrenia )

4. Abdominal surgery.

5. Major medical diseases. ( ex. heart failure, myocardial infarction, chronic obstructive pulmonary disease, kidney failure, cancer, stroke )

6. The patient refused to sign informed consent form.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Irritable Bowel Syndrome
• Syndrome

Intervention

Drug:
• Xiang-Sha-Liu-Jun-Zi-Tang
Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
• Placebo
Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .

Locations

Country	Name	City	State
Taiwan	China Medical University Hospital	Taichung

Sponsors (1)

Lead Sponsor	Collaborator
China Medical University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	WHO Quality Questionnaire		Change from baseline WHO Quality of Life-BREF score at week 4 (28 ± 5 days) and week 12 (84 ± 7 days)	Yes
Primary	Gastrointestinal System Rating Scale-IBS Questionnaire		Change from baseline Gastrointestinal System Rating Scale-IBS score at week 4 (28 ± 5 days) and week 12 (84 ± 7 days)	Yes
Secondary	IBS-QOL Questionnaire		Change from baseline IBS-QOL score at week 4 (28 ± 5 days) and week 12 (84 ± 7 days)	Yes